Lesley Kahl

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 338 citations

Treatment And Prevention, Human Retrovirus, Antiviral Therapy +8

Oral <i>Salmonella typhimurium</i> (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.

Dong Yang, Neil F. Fairweather, Linda L. Button et al. · The Journal of Immunology · 1990 · 187 citations · Full text

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud, Chloe Orkin, Daniel Podzamczer et al. · The Lancet HIV · 2019 · 110 citations

Treatment And Prevention, Antiviral Drug Development, Antiviral Therapy +9

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

Lesley Kahl, Jessal J. Patel, Mark Layton et al. · Lupus · 2016 · 66 citations

Immunodeficiencies, Immunology, Pharmacotherapy +18

Vaccination against murine cutaneous leishmaniasis by using <i>Leishmania major</i> antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

Lesley Kahl, Connor A. P. Scott, Rosalia Lelchuk et al. · The Journal of Immunology · 1989 · 57 citations · Full text